More so, it has been suggested that therapeutic efficacy of thalidomide and lenalidomide in MM in part relies on their ability to inhibit pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6 [80,81]. Here, TNF is linked to Miyoshi myopathy.